


AMENDED CLAIM SET:


1. (original) A compound of general formula (I):



or an N-oxide thereof, or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, wherein

R^5 is halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, alkyl, alkoxy, -alkyl-OR^a, -CH=N-O-R^a or -(C=O)-O-alkyl; wherein R^a is hydrogen or alkyl;

R^7 is



wherein one of R^b and R^c is hydrogen; and the other of R^b and R^c is

- hydrogen, halo, cyano, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, alkylcarbonyl or -NR^d-(C=O)-R^e; wherein the alkyl and alkoxy are optionally substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, halo, and -NR'R''; R^d and R^e independently of each other are selected from hydrogen and alkyl; R' and R'' independently of each other are selected from hydrogen and alkyl;

- $-NR^fR^g$, $-alkyl-NR^fR^g$, $-(C=O)-NR^fR^g$, $-O-NR^fR^g$, $-O-alkyl-NR^fR^g$, $-NR^h-alkyl-NR^fR^g$; wherein R^h is hydrogen or alkyl; R^f and R^g independently of each other are hydrogen or alkyl; or R^f and R^g together with the nitrogen to which they are attached form a 5- to 7-membered heterocyclic ring, which heterocyclic ring may optionally comprise as a ring member, one oxygen atom, and/or one additional nitrogen atom, and/or one carbon-carbon double bond, and/or one carbon-nitrogen bond; and which heterocyclic ring may optionally be substituted with trifluoromethyl, alkyl, hydroxyalkyl, or $-NR'R''$; wherein R' and R'' independently of each other are hydrogen or alkyl; or R^b and R^c together represent $-O-CH_2-O-$;

or R^7 is

- $-NR^h-(C=O)-R^i$, $-N=CH-R^i$, or $-C\equiv C-R^i$; wherein R^h is hydrogen or alkyl; and R^i is alkyl or phenyl, which alkyl or phenyl is optionally substituted with hydroxy, trifluoromethyl, cyano or alkyl; or
- $-NR^jR^k$, $-alkyl-NR^jR^k$, $-CH=CH-(C=O)-NR^jR^k$, $-CH=CH-(C=O)-O-alkyl$, $-alkyl-(C=O)-NR^jR^k$, or $-C\equiv C-CH_2-NR^jR^k$; wherein R^j and R^k independently of each other are selected from the group consisting of hydrogen, alkyl, $-alkyl-CN$, $-alkyl-R'R''$ and $-alkyl-R^l$; wherein R' and R'' independently of each other are hydrogen or alkyl; R^l is a 5- to 7-membered heterocyclic ring comprising one nitrogen atom, which heterocyclic ring may optionally comprise as a ring member, one oxygen atom, and/or one additional nitrogen atom, and/or one carbon-carbon double bond, and/or one carbon-nitrogen bond; and which heterocyclic ring may optionally be substituted with trifluoromethyl, alkyl, hydroxyalkyl, or $-NR'R''$; wherein R' and R'' independently of each other are hydrogen or alkyl; or R^j and R^k together with the nitrogen to which they are attached form a 5- to 7-membered heterocyclic ring, which heterocyclic ring may optionally comprise as a ring member, one oxygen atom, and/or one additional nitrogen atom, and/or one carbon-carbon double bond, and/or one carbon-nitrogen bond; and which heterocyclic ring may optionally be substituted with trifluoromethyl, alkyl, hydroxy, hydroxyalkyl, or $-NR'R''$; wherein R' and R'' independently of each other are hydrogen or alkyl;

or R^7 is a heteroaryl group which heteroaryl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, alkyl, and alkoxy;

with the proviso that the compound is not

7-(3-Aminophenyl)-1-phenyl-5-trifluoromethylbenzimidazole,

7-(3-Pyridyl)-1-phenyl-5-trifluoromethylbenzimidazole,


1,7-Diphenyl-5-trifluoromethylbenzimidazole,

7-benzoylamino-1-phenyl-5-trifluoromethylbenzimidazole, or

7-amino-1-phenyl-5-trifluoromethylbenzimidazole.

2. (original) The compound of claim 1, wherein R^5 is selected from the group of methyl, tertbutyl, trifluoromethyl, hydroxymethyl, cyano, ethoxycarbonyl, $-\text{CH}=\text{N}-\text{OH}$, and $-\text{CH}=\text{N}-\text{O}-\text{CH}_3$.

3. (previously presented) The compound of claim 1, wherein R^7 is



wherein one of R^b and R^c is hydrogen; and

the other of R^b and R^c is

- hydrogen, halo, cyano, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, alkylcarbonyl or $-\text{NR}^d-(\text{C}=\text{O})-\text{R}^e$; wherein the alkyl and alkoxy are optionally substituted with one or more substituents selected from the group consisting of: hydroxy, alkoxy, halo, and $-\text{NR}'\text{R}''$;

- $-\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{alkyl}-\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-(\text{C}=\text{O})-\text{NR}^{\text{f}}\text{R}^{\text{g}}$, $-\text{O}-\text{NR}^{\text{f}}\text{R}^{\text{g}}$; $-\text{O}-\text{alkyl}-\text{NR}^{\text{f}}\text{R}^{\text{g}}$; $-\text{NR}^{\text{h}}-\text{alkyl}-\text{NR}^{\text{f}}\text{R}^{\text{g}}$; wherein R^{d} , R^{e} , R^{f} , R^{g} , R^{h} , R' and R'' are as defined in claim 1.

4. (previously presented) The chemical compound of claim 1, wherein R^7 is 3,4-methylenedioxyphenyl.

5. (previously presented) The chemical compound of claim 1, wherein R^7 is R^7 is

- $-\text{NR}^{\text{h}}-(\text{C}=\text{O})-\text{R}^{\text{i}}$, $-\text{N}=\text{CH}-\text{R}^{\text{i}}$, or $-\text{C}\equiv\text{C}-\text{R}^{\text{i}}$;
wherein R^{h} is hydrogen or alkyl; and R^{i} is alkyl or phenyl, which alkyl or phenyl is optionally substituted with hydroxy, trifluoromethyl, cyano or alkyl; or
- $-\text{NR}^{\text{j}}\text{R}^{\text{k}}$, $-\text{alkyl}-\text{NR}^{\text{j}}\text{R}^{\text{k}}$, $-\text{CH}=\text{CH}-(\text{C}=\text{O})-\text{NR}^{\text{j}}\text{R}^{\text{k}}$, $-\text{CH}=\text{CH}-(\text{C}=\text{O})-\text{O}-\text{alkyl}$, $-\text{alkyl}-(\text{C}=\text{O})-\text{NR}^{\text{j}}\text{R}^{\text{k}}$, or $-\text{C}\equiv\text{C}-\text{CH}_2-\text{NR}^{\text{j}}\text{R}^{\text{k}}$; wherein R^{j} and R^{k} independently of each other are selected from the group consisting of hydrogen, alkyl, $-\text{alkyl}-\text{CN}$, $-\text{alkyl}-\text{R}'\text{R}''$ and $-\text{alkyl}-\text{R}^{\text{l}}$; wherein R' and R'' independently of each other are hydrogen or alkyl; R^{l} is a 5- to 7-membered heterocyclic ring comprising one nitrogen atom, which heterocyclic ring may optionally comprise as a ring member, one oxygen atom, and/or one additional nitrogen atom, and/or one carbon-carbon double bond, and/or one carbon-nitrogen bond; and which heterocyclic ring may optionally be substituted with trifluoromethyl, alkyl, hydroxyalkyl, or $-\text{NR}'\text{R}''$; wherein R' and R'' independently of each other are hydrogen or alkyl; or R^{j} and R^{k} together with the nitrogen to which they are attached form a 5- to 7-membered heterocyclic ring, which heterocyclic ring may optionally comprise as a ring member, one oxygen atom, and/or one additional nitrogen atom, and/or one carbon-carbon double bond, and/or one carbon-nitrogen bond; and which heterocyclic ring may optionally be substituted with trifluoromethyl, alkyl, hydroxy, hydroxyalkyl, or $-\text{NR}'\text{R}''$; wherein R' and R'' independently of each other are hydrogen or alkyl.

6. (currently amended) The chemical compound of claim 1, wherein R^7 is indolyl, pyridyl, or furyl, optionally substituted with halo or methyl.

7. (original) The compound of claim 1, which is

7-(3-Chlorophenyl)-1-phenyl-5-trifluoromethylbenzimidazole;

7-(3-Aminophenyl)-5-formyl-1-phenylbenzimidazole oxime;

O-Methyl 7-(3-Aminophenyl)-5-formyl-1-phenylbenzimidazole oxime;

7-(N-benzylideneamino)-1-phenyl-5-trifluoromethylbenzimidazole;

7-(N-(4-cyanobenzylidene)amino)-1-phenyl-5-trifluoromethylbenzimidazole;

7-(N-(3-cyanobenzylidene)amino)-1-phenyl-5-trifluoromethylbenzimidazole;

7-(3-Aminophenyl)-5-cyano-1-phenylbenzimidazole;

7-(3-(Hydroxymethyl)phenyl)-1-phenyl-5-trifluoromethylbenzimidazole;

1-Phenyl-7-(3-(1,2,3,6-tetrahydropyridine-1-ylmethyl)phenyl)-5-trifluoromethyl-benzimidazole;

7-(3-Acetamidophenyl)-5-ethoxycarbonyl-1-phenylbenzimidazole;

7-(3-Aminophenyl)-5-ethoxycarbonyl-1-phenylbenzimidazole;

5-(Ethoxycarbonyl)-7-(3-(hydroxymethyl)phenyl)-1-phenylbenzimidazole;

7-(3-Cyanophenyl)-1-phenyl-5-trifluorophenylbenzimidazole;

5-Cyano-7-(3-nitrophenyl)-1-phenylbenzimidazole;

5-Cyano-7-(3-hydroxymethylphenyl)-1-phenylbenzimidazole;

5-Cyano-7-(3-((1-methylpiperazin-4-yl)methyl)phenyl)-1-phenylbenzimidazole;

5-Cyano-7-(3-(diethylaminomethyl)phenyl)-1-phenylbenzimidazole;

7-(3-Acetamidophenyl)-5-cyano-1-phenylbenzimidazole;

5-Cyano-7-(4-methoxyphenyl)-1-phenylbenzimidazole;

5-Cyano-7-(3-methoxyphenyl)-1-phenylbenzimidazole;

5-Cyano-7-(4-cyanophenyl)-1-phenylbenzimidazole;

5-Cyano-7-(3-fluorophenyl)-1-phenylbenzimidazole;

5-Cyano-7-(4-hydroxyphenyl)-1-phenylbenzimidazole;

5-Cyano-7-[3-(dimethylamino)phenyl]-1-phenylbenzimidazole;

5-Cyano-7-(3,4-methylenedioxyphenyl)-1-phenylbenzimidazole;

5-Cyano-7-(pyridin-4-yl)-1-phenylbenzimidazole;

7-(3-Aminophenyl)-5-hydroxymethyl-1-phenylbenzimidazole;

5-Ethoxycarbonyl-7-(3-((morpholin-4-yl)methyl)phenyl)-1-phenylbenzimidazole;

5-Ethoxycarbonyl-7-(3-((1-methylpiperazin-4-yl)methyl)phenyl)-1-phenylbenzimidazole;
5-Ethoxycarbonyl-7-(3-((dimethylamino)methyl)phenyl)-1-phenylbenzimidazole;
5-Cyano-7-(3-cyanophenyl)-1-phenylbenzimidazole;
5-Cyano-7-(4-nitrophenyl)-1-phenylbenzimidazole;
7-(4-Acetamidophenyl)-5-cyano-1-phenylbenzimidazole;
7-(3-Acetamidophenyl)-1-phenyl-5-trifluoromethylbenzimidazole;
O-Methyl 7-(3-acetamidophenyl)-5-formyl-1-phenylbenzimidazole oxime;
O-Methyl 7-(3-(dimethylamino)phenyl)-5-formyl-1-phenylbenzimidazole oxime;
5-Cyano-7-(4-diethylaminomethylphenyl)-1-phenylbenzimidazole;
7-(4-Benzamidyl)-5-cyano-1-phenylbenzimidazole;
7-(3-Acetamidophenyl)-5-hydroxymethyl-1-phenylbenzimidazole;
7-(3-Ethylaminophenyl)-5-hydroxymethyl-1-phenylbenzimidazole;
7-(3-Dimethylaminophenyl)-5-trifluoromethyl-1-phenylbenzimidazole;
7-(3-Methylaminophenyl)-5-trifluoromethyl-1-phenylbenzimidazole;
1-Phenyl-7-(3-((4-methylpiperazin-1-yl)methyl)phenyl)-5-trifluoromethylbenzimidazole;
7-(3-(1-Morpholinylmethyl)phenyl)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(3-((Dimethylamino)methyl)phenyl)-1-phenyl-5-trifluoromethylbenzimidazole;
5-Cyano-7-(4-(2-(4-morpholino)ethoxy)phenyl)-1-phenylbenzimidazole;
7-(3-(N-Methyl acetamido)phenyl)-1-phenyl-5-trifluoromethylbenzimidazole;
1-Phenyl-7-(4-pyridyl)-5-trifluoromethylbenzimidazole;
5-(Hydroxymethyl)-1-phenyl-7-(3-trifluoromethoxyphenyl)benzimidazole;
7-(4-pyridyl N-oxide)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(3-chloro-4-pyridyl)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(3-chloro-4-pyridyl-N-oxide)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(3-Acetylphenyl)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(3-Fluorophenyl)-1-phenyl-5-trifluorophenylbenzimidazole;
3-(3-Phenyl-6-trifluoromethyl-3H-benzimidazol-4-yl)acrylic acid methyl ester;
3-(6-Cyano-3-phenyl-3H-benzimidazol-4-yl)acrylic acid methyl ester;
7-(4-Morpholinyl)-1-phenyl-5-trifluoromethylbenzimidazole;

5-*t*-Butyl-7-(3-dimethylaminophenyl)-1-phenylbenzimidazole;
7-(3-(1-Methoxyethyl)phenyl)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(1-Methyl-5-indolyl)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(3-(1-Hydroxyethyl)phenyl)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(3-Furyl)-1-phenyl-5-trifluoromethylbenzimidazole;
N,N-Diethyl-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)acrylamide;
1-(4-Methylpiperazin-1-yl)-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)prop-2-en-1-one;
3-(3-Phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)-1-piperidinylprop-2-en-1-one;
1-(4-Morpholinyl)-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)prop-2-en-1-one;
1-(4-Methyl-[1,4]-hexahydrodiazepin-1-yl)-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)prop-2-en-1-one;
N-(2-Cyanoethyl)-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)acrylamide;
3-(3-Phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)-*N*-propylacrylamide;
N-(2-Dimethylaminoethyl)-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)acrylamide;
3-(3-Phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)-1-(4-trifluoromethyl-piperidin-1-yl)prop-2-en-1-one;
7-(3-(2-Hydroxy-2-propyl)phenyl)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(4-Hydroxypiperidinyl)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(3-Fluorophenyl)-5-methyl-1-phenylbenzimidazole;
7-(4-Hydroxybut-1-ynyl)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(1-(1-(4-Hydroxyethylpiperazinyl)ethyl)-1-methylamino)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(1-(1-(4-Methylpiperazinyl)ethyl)-1-methyl)amino-1-phenyl-5-trifluoromethylbenzimidazole;
7-(3-(4-Morpholino)prop-1-ynyl)-1-phenyl-5-trifluoromethylbenzimidazole;
N,N-Diethyl-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)propionamide;
3-(6-*tert*-Butyl-3-phenyl-3*H*-benzimidazol-4-yl)-1-(piperidin-1-yl)prop-2-en-1-one;
N-Ethyl-*N*-isopropyl-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)acrylamide;

N-(1-Methylpiperidin-4-yl)methyl-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)-acrylamide;
N-Methyl-*N*-(1-methylpyrrolidin-3-yl)-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)acrylamide;
3-(6-*tert*-Butyl-3-phenyl-3*H*-benzimidazol-4-yl)-*N*-methyl-*N*-(1-methylpiperidin-4-yl)-acrylamide;
7-(4-(Diethylamino)butyl)-1-phenyl-5-trifluoromethylbenzimidazole;
7-(4-((*N*-(2-Cyanoethyl)-*N*-methyl)amino)-1-butyl)-1-phenyl-5-trifluoromethylbenzimidazole;
3-(3-Phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)-1-(pyrrolidin-1-yl)prop-2-en-1-one;
1-(2,5-Dihydropyrrol-1-yl)-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)prop-2-en-1-one;
N-(2-Cyanoethyl)-*N*-methyl-3-(3-phenyl-6-trifluoromethyl-3*H*-benzimidazol-4-yl)acrylamide;
1-Phenyl-7-(3-(1-(1,2,3,6-tetrahydropyridinyl))prop-1-ynyl)-5-trifluoromethylbenzimidazole;
1-Phenyl-7-(3-(1-piperidinyl)prop-1-ynyl)-5-trifluoromethylbenzimidazole;
7-[1-(3-Dimethylamino)pyrrolidinyl]-1-phenyl-5-trifluoromethylbenzimidazole;
or an *N*-oxide thereof, or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.

8. (previously presented) A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 1, or the compound
7-(3-Aminophenyl)-1-phenyl-5-trifluoromethylbenzimidazole,
7-(3-Pyridyl)-1-phenyl-5-trifluoromethylbenzimidazole,
1,7-Diphenyl-5-trifluoromethylbenzimidazole,
7-benzoylamino-1-phenyl-5-trifluoromethylbenzimidazole, or
7-amino-1-phenyl-5-trifluoromethylbenzimidazole,
or an *N*-oxide thereof, or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

9. (withdrawn) Use of the chemical compound of claim 1, or the compound 7-(3-Aminophenyl)-1-phenyl-5-trifluoromethylbenzimidazole, 7-(3-Pyridyl)-1-phenyl-5-trifluoromethylbenzimidazole, 1,7-Diphenyl-5-trifluoromethylbenzimidazole, 7-benzoylamino-1-phenyl-5-trifluoromethylbenzimidazole, or 7-amino-1-phenyl-5-trifluoromethylbenzimidazole, or an N-oxide thereof or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament.

10. (withdrawn) A method for treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the GABA_A receptor complex in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to claim 1 or the compound 7-(3-aminophenyl)-1-phenyl-5-trifluoromethylbenzimidazole, 7-(3-pyridyl)-1-phenyl-5-trifluoromethylbenzimidazole, 1,7-diphenyl-5-trifluoromethylbenzimidazole, 7-benzoylamino-1-phenyl-5-trifluoromethylbenzimidazole, or 7-amino-1-phenyl-5-trifluoromethylbenzimidazole, or an N-oxide thereof, or any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.

11. (withdrawn) The method according to claim 10, wherein the disease, disorder or condition is anxiety disorder, panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, phobia, animal phobia, social phobia, obsessive-compulsive disorder, generalized or substance-induced anxiety disorder, stress disorder, post-traumatic and acute stress disorder, sleep disorder, memory disorder, convulsive disorder, epilepsy, febrile convulsions in children, premenstrual syndrome, muscle spasm or spasticity, effects of substance abuse or dependency, effects of alcohol withdrawal, or disorder of circadian rhythm.

12. (withdrawn) The method according to claim 10, for inducing and maintaining anaesthesia, sedation and muscle relaxation or for pre-medication prior to anaesthesia or minor procedures such as endoscopy, including gastric endoscopy.

13. (cancelled).